{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:26:52Z","timestamp":1768321612431,"version":"3.49.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,8]],"date-time":"2011-09-08T00:00:00Z","timestamp":1315440000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0024180","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:42:18Z","timestamp":1315528938000},"page":"e24180","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["A Randomized, Placebo Controlled, Double Masked Phase IB Study Evaluating the Safety and Antiviral Activity of Aprepitant, a Neurokinin-1 Receptor Antagonist in HIV-1 Infected Adults"],"prefix":"10.1371","volume":"6","clinical-trial-number":[{"clinical-trial-number":"nct00428519","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Pablo","family":"Tebas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florin","family":"Tuluc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey S.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaquing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Gonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Korelitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven D.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"FJ Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.","volume":"46","author":"M Markowitz","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","article-title":"Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.","volume":"369","author":"B Grinsztejn","year":"2007","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0140-6736(07)60571-6","article-title":"Raltegravir: a new antiretroviral class for salvage therapy.","volume":"369","author":"P Cahn","year":"2007","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/nm1511","article-title":"Microbial translocation is a cause of systemic immune activation in chronic HIV infection.","volume":"12","author":"JM Brenchley","year":"2006","journal-title":"Nature Medicine"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1086\/524143","article-title":"Relationship between T cell activation and CD4(+) T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.","volume":"197","author":"PW Hunt","year":"2008","journal-title":"Journal of Infectious Diseases"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00042560-199710010-00003","article-title":"Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.","volume":"16","author":"Z Liu","year":"1997","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1086\/314660","article-title":"Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.","volume":"179","author":"JV Giorgi","year":"1999","journal-title":"J Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1182\/blood-2003-09-3333","article-title":"Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.","volume":"104","author":"SG Deeks","year":"2004","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11910-008-0073-3","article-title":"HIV-associated neurocognitive disorders and the impact of combination antiretroviral therapies.","volume":"8","author":"BM Ances","year":"2008","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","article-title":"HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.","volume":"75","author":"RK Heaton","year":"2010","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment.","volume":"355","author":"WM El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(06)68887-9","article-title":"CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial.","volume":"367","author":"C Danel","year":"2006","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/pr.54.2.285","article-title":"The tachykinin peptide family.","volume":"54","author":"C Severini","year":"2002","journal-title":"Pharmacol Rev"},{"key":"ref15","author":"I Marriott","year":"2001"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/00002030-200110190-00019","article-title":"Elevated substance P levels in HIV-infected men.","volume":"15","author":"SD Douglas","year":"2001","journal-title":"Aids"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/aid.2007.0207","article-title":"Elevated substance P levels in HIV-infected women in comparison to HIV-negative women.","volume":"24","author":"SD Douglas","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1073\/pnas.071052298","article-title":"Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes.","volume":"98","author":"JP Lai","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1097\/QAD.0b013e3283405c33","article-title":"Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals.","volume":"24","author":"MM Manak","year":"2010","journal-title":"Aids"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11481-008-9117-3","article-title":"Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia\/macrophages.","volume":"3","author":"X Wang","year":"2008","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/CVI.00406-08","article-title":"Novel method for determination of substance P levels in unextracted human plasma by using acidification.","volume":"16","author":"DE Campbell","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jpba.2008.12.005","article-title":"A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research.","volume":"49","author":"D Wu","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1073\/pnas.0806632105","article-title":"Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor.","volume":"105","author":"JP Lai","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1176\/ajp.2006.163.4.637","article-title":"Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression.","volume":"163","author":"TD Geracioti","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref25","article-title":"Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor.","author":"L Monaco-Shawver","year":"2010","journal-title":"J Leukoc Biol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1086\/605890","article-title":"Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells.","volume":"200","author":"MA French","year":"2009","journal-title":"J Infect Dis"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1086\/374786","article-title":"T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.","volume":"187","author":"PW Hunt","year":"2003","journal-title":"J Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1086\/511681","article-title":"Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.","volume":"44","author":"A Landay","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction.","volume":"349","author":"N Friis-Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","article-title":"Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.","volume":"5","author":"LH Kuller","year":"2008","journal-title":"PLoS Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/QAI.0b013e3181e66216","article-title":"Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.","volume":"55","author":"PC Tien","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref32","article-title":"HIV-associated neurocognitive impairment remains prevalent in the era of combination ART: the CHARTER study.","author":"R Heaton","year":"2009"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1126\/science.281.5383.1640","article-title":"Distinct mechanism for antidepressant activity by blockade of central substance P receptors.","volume":"281","author":"MS Kramer","year":"1998","journal-title":"Science"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biopsych.2005.07.013","article-title":"Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.","volume":"59","author":"M Keller","year":"2006","journal-title":"Biol Psychiatry"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/0091270005283467","article-title":"Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers.","volume":"46","author":"AK Majumdar","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"ref36","article-title":"Drug approval Package. EMEND (aprepitant) Capsules.","year":"2003"},{"key":"ref37","article-title":"Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the Substance P receptor antagonist aprepitant.","author":"RI Sanchez","year":"2004","journal-title":"Drug Metab Dispos"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0024180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T18:57:05Z","timestamp":1540321025000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0024180"}},"subtitle":[],"editor":[{"given":"Andrew D.","family":"Badley","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,8]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0024180","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,8]]}}}